- Roche will acquire PathAI and integrate its AISight Image Management System into Roche Diagnostics.
- Deal terms: $750 million upfront plus up to $300 million in milestone payments.
- Closing expected in the second half of the year, subject to customary regulatory and antitrust approvals.
Deal overview
Roche has entered a definitive merger agreement to acquire PathAI; the acquired entity will join Roche's Diagnostics division pending closing. The transaction includes an upfront payment of USD 750 million and up to USD 300 million in milestone payments.
Technology and integration
Roche will integrate PathAI’s AISight Image Management System (IMS) and AI analysis/workflow capabilities into its digital pathology portfolio to support conversion of slide-based workflows into high-resolution digital images and automated, AI-driven processes.
Biopharma and clinical implications
Combining PathAI’s AI platform with Roche’s companion-diagnostics expertise is positioned to support clinical trial operations, translational research, biomarker discovery and the development of new diagnostic tools, aiming to accelerate precision-medicine approaches and targeted therapies.
Timing and approvals
Closing is subject to customary conditions, including antitrust and regulatory approvals, and is currently expected in the second half of the year.
